[00:00:00] Carl Lanore: [00:00:00] Hey, Hey, welcome back to another episode of superhuman radio. Today's a special edition of the pep talk. We're going to be joined by Ryan Smith in just a moment as he makes his maiden voyage, has made an appearance on the show long overdue, long overdue. In fact, when I originally asked Ryan to do the show, he didn't want to do it.

[00:00:16] But I think that he's been doing so many podcasts now, uh, that, uh, this is just, uh, another day in the park for him. Uh, I want to mention that today is November 27th. 2019 for those of you listening to this show a hundred years from now, when you realize that we knew a lot of stuff before anybody else did, um, we put that time stamp on, and also I'm wearing my hunt with the Henry swag today.

[00:00:41] You can get a free catalog from Henry rifle, Henry Tyler. Henry revolutionized. Uh, rifles. He took them from single shot to repeat, or he's the guy who invented the lever action, not Winchester. Winchester took all the credit. Uh, you can right now get a beautiful catalog, absolutely free. That's worthy of putting on your coffee [00:01:00] table of the Henry rifles by going to super human radio.net and clicking the Henry a banner ad.

[00:01:06] And let's bring our guest on now. And that is Ryan Smith. How you doing, Ryan?

[00:01:11] Ryan Smith: [00:01:11] Hey doing. All right. Thanks for having me. You're definitely right. It's long overdue.

[00:01:15] Carl Lanore: [00:01:15] Yeah, I know, right? We talked about it a long time ago and you just kind of, you weren't ready to, I think at that time, and I, I'm paraphrasing, you just weren't ready to become the face of this movement, and this is a movement.

[00:01:27] You know, the pep talk is by far my most popular show that I do, and that's because people realize that peptides for the first time ever make good on the promises of modern medicine. In that. There are ways of fixing and correcting problems as opposed to masking symptoms. Uh, and, and it's very exciting.

[00:01:46] There's a lot of people out there literally changing their health, uh, with their doctor's help, uh, in ways that they could have never done before. And I, and I have to give credit where [00:02:00] credit is due if it wasn't for TaylorMade. And I'll tell you why I say that. Because TaylorMade made the initial investment into the amino acid sequences and put themselves on the line and put themselves out there.

[00:02:12] You and Jeremy Delk put yourselves out there and blaze the frontier. You guys are the tip of the spear and, and, and you, and you get pushed back. I know. Uh, but the reality is if it really wasn't for tailor made, I mean, I remember seeing you guys at a forum. Back in the day talking about CJC 1295 and I was saying to dr seeds, how could these guys be talking about that?

[00:02:39] So kudos to your team.

[00:02:43] Ryan Smith: [00:02:43] Yeah. Thank you. No. Yeah, you're absolutely right. It's, uh, you know, the, the amount of demand we've gotten is overwhelming because clinicians are seeing the exact same thing that you're mentioning. Yeah. You know, patients are being able to, uh, to, to be, uh, treated better with better tools, um, with less side effects and more specificity.

[00:03:00] [00:02:59] So all in all, the peptides are. Are definitely growing. And right now, you know, I gave a talk in 2016 where I said there were 62 approved FDA peptides. Now the numbers are 103 years later. I mean, and so the expansion doctors from our clinical usage, but also from the industry as a whole, it's just a phenomenal, and we're excited to be writing that way.

[00:03:19] Carl Lanore: [00:03:19] And for those of you tuning into this show, and you are a clinician and you're thinking, how do I take advantage of this, this movement here in medicine? And it really is a movement. And it's being driven by the patients. By the way, I'm going to tell you something. Um, and you think to yourself, okay, so I want to do something.

[00:03:38] Uh, the organization that, uh, that, that tailor made supports is the international peptide society and Dr. William seed, who is also, he's, he really is discovering and in some cases trying to come up with new peptides. Uh, and if so, you want to be trained so that you can responsibly prescribe peptides to your patients.

[00:04:00] [00:04:00] Then you go to a peptide society.org and you sign up, you take the classes, and you become a leader in a field that I promise you, if 10 years from now is going to be the core of the way we treat disease. And so you could get on board and then you're able to prescribe, uh, through tailor made. So.

[00:04:20] We are breaking the news on a brand new peptide that has not been discussed. I know that you, you may have eluded to this peptide in other podcasts, but you never really talked about it, but now you're ready to start talking about it and it's called five amino one MQ.

[00:04:34] Ryan Smith: [00:04:34] Right. Yeah, absolutely. And, and, and I, I hate to say it, but this one is one of the very, very few, uh, the, we actually do as a small molecule.

[00:04:42] And one of the reasons we've went this way is because, um, it's really bioavailable. Um, and so the enzyme target that we're trying to treat with five minute one Q, uh, is, is, uh, called anonymity. But, uh, this has actually been able to do as a, as a small molecule and not as a

[00:04:58] Carl Lanore: [00:04:58] peptide. So when we say a [00:05:00] small molecule.

[00:05:01] Um, it it, this is not a S a sequence of amino acid. You're saying it's not a protein. Correct.

[00:05:08] Ryan Smith: [00:05:08] So one of the data there was originally gathered on this enzyme. They used, uh, peptides to inhibit this enzyme. But, um, the, one of the biggest issues with the peptide, it's against stability, half-life, and then oral bioavailability.

[00:05:20] Most of these are subcutaneous injections. And so this, this was sort of created as a result. You get all those, uh, more positive pharmaceutical, uh, attributes.

[00:05:29] Carl Lanore: [00:05:29] So what, what is the molecular weight of a five amino one MQ? If I could ask.

[00:05:34] Ryan Smith: [00:05:34] Yeah. To be honest, I don't know off the top of my head, but it's, it's relatively small.

[00:05:38] Um, and, uh, it's a but completely novel. The, the trials had been released out of Galveston. Uh, they initially looked at 70 different molecules based off of, you know, the stage screenings, um, where they were able to predict, uh, which ones are going to be able to inhibit this complex the most.

[00:05:54] Um, and outhaul the 71 with the press pharmaceutical, uh, attributes with the five of me. Know what I'm [00:06:00] cute.

[00:06:00] Carl Lanore: [00:06:00] Now. Uh, the interesting thing about this is that it somehow is related to, uh, the pathway of a very, very favorite, uh, both injectable and oral supplement today. And that's an a D plus, right?

[00:06:16] Ryan Smith: [00:06:16] Absolutely. And that's one of the reasons it definitely got our eyes because, um, you know, as we talk about the, you know, reversing disease, one of the biggest things we have to talk about are the changes to the epigenetic genome. Um, and, and. There's are two wings. And so, um, NAD is a cofactor for the situations.

[00:06:37] And so any way we can affect that pathway in a positive way means that we can really reduce the incidence of aging and disease. And so, uh, that's one of the reasons we started to focus on it initially.

[00:06:47] Carl Lanore: [00:06:47] Now, um. Talk about the, uh, they're, they're not a big body of evidence about this peptide, but I know that you and dr seeds have been working behind the scenes [00:07:00] to extrapolate science that relates to this enzyme.

[00:07:03] Maybe they were doing research in another area, and this enzyme appeared and was, was tracked and written about, but this, this enzyme has some really promising attributes right.

[00:07:16] Ryan Smith: [00:07:16] Absolutely. This, this enzyme is, um, is highly correlated to a metabolic disease, um, obesity. And that's one of the biggest targets for, it's also highly linked to things like liver cirrhosis, uh, Parkinson's disease, um, and a lot of other disease States.

[00:07:34] And so, uh, one of the most interesting things though, important thing about it is that this enzyme actually increases as you age, and it increases with, uh, adiposity possibly. So as you. Started having metabolic stress, like type two diabetes, you actually increase this enzyme. And so, um, having a target for this enzyme where we can.

[00:07:52] Basically block its effect. Um, and what happens is this ends, I'm actually converts a nicotine  to, [00:08:00] uh, essentially one methylnicotinamide. And when it does that, it takes it away from the nav salvage pathway, so it's not in a min, and then therefore it's not able to go to NAD. And so it's basically a shunt for to get basically what are, we're in a D level.

[00:08:15] And by blocking this shot, we're able to increase those energy levels back to where they should be. Um, and so obviously that has all the effects we're talking about, but in particular has ridiculously positive effects as it relates to metabolism, particularly in white adipose tissue and in muscle cells.

[00:08:31] And so in those two particular tissues were able to increase that Mav level and significantly increase metabolism.

[00:08:37] Carl Lanore: [00:08:37] Now, now the entry of this enzyme, this, this molecule, uh, starts to. Separate out the discussion about intracellular and extracellular NAD plus. So right now, people are supplementing with tons of NAD plus, uh, and, and even injecting and going for infusions, a I V infusions.

[00:09:00] [00:08:59] But there is some evidence that this could actually exacerbate some disease States. And, and it opens the discussion about intracellular and extracellular NAD and it, this molecule affects the, it increases intracellular, which is more important

[00:09:17] Ryan Smith: [00:09:17] right. Exactly. And, and you know, extracellular NAD is a, is a very hard, um, it's a very hard measurement too, because if you realize any red blood cells or any cells in the body, you release a lot of NAD.

[00:09:30] And so you could have fluctuations of 1000% either way with this extra cellular level. So the intracellular level is really what we're focusing on, uh, and more important. And with that being said, the, um, you know, there are a lot of other therapies, like, you know, the NAD. Uh, the nicotine and my drive aside, which is, you know, done in some supplements and in the, in a men, which has also done all his precursors to NAD.

[00:09:51] And we know that the enemy in an neonate, nicotinamide riboside have cellular transporters. So there are ways to get into the cell and then convert to an ID. [00:10:00] So both of those look like promising strategies. But I think that the, the jury is a little bit out on what NAD therapy is doing as it relates to.

[00:10:09] Yeah. The other thing I should note is you're exactly right with a NAD maybe even being a negative factor for some diseases. You know, if we know that it increases or exacerbates senescence, which is, you know, one of those, the biggest hallmarks of aging. Um, and uh, and so obviously, you know, the treatment strategies that include in ID or nav optimization should really take that into account as well.

[00:10:31] Carl Lanore: [00:10:31] So, um, talk about, so this enzyme. Uh, rises as we age is this enzyme found as part of the, uh, people are 50 cascade.

[00:10:43] Ryan Smith: [00:10:43] So it's not, it's, it's a, it's an interstellar enzyme that is really expressed in the majority of brain, kidneys, liver, muscle, and fat tissues. Um, and so it, it's in the liver mainly because it handles methylation.

[00:10:58] What happens is, uh, you [00:11:00] know, it as it converts to one methyl. Uh, nicotine . It's taking that methyl group from CME and or from the essence  and that is one of the, it's actually the second most, uh, common cofactor in the body outside of the ADU ACP. Um, and so it's involved in a ton of different processes and, and particularly in metabolism processes.

[00:11:22] And so, uh, it's found a lot in the liver, but. Also in the muscle and fat tissue. And those are probably the two biggest areas where we can affect change. Um, and, and the studies have shown that if you don't mind, I, I definitely want to go into what we have seen in, in some of the, the trials, just because,

[00:11:40] Carl Lanore: [00:11:40] please.

[00:11:41] Ryan Smith: [00:11:41] There's not a ton of data out there, but the data that has been used have shown a couple of really, really interesting things. So it really, two great in vivo studies in mice. One with that, uh, how this effective metabolism and white adipose tissue. Um, and what they found is they basically treated mice with diet, uh, induced [00:12:00] obesity.

[00:12:00] So high fat diet mice that should gain weight. Um, and whenever they were treated with this, they lost around 6% of their, of their body weight, um, in 11 days. Um, and the mice we weren't having, did not have, this, had an increase of around 1.5% embodied weight, um,

[00:12:18] Carl Lanore: [00:12:18] in that same 11 days. Same

[00:12:20] Ryan Smith: [00:12:20] 11 days.

[00:12:21] We also, we also know that, uh, there was essentially a 30% decrease in adipocyte size and a 40% decrease in adipocyte volume, um, in those same mice. And along with that, they saw cholesterol reductions, um, total cholesterol reductions around 30%. And so all in all, if this is, has a very, very favorable metabolic profile, and that's before we even get to the muscle.

[00:12:45] Um, and so, uh, one of the other things about it though, is it preventative diet induced obesity. Um, and so even if you were to take this as a preventative measure, you reduce your ability. Uh, for life agenesis bio almost 70%. And so, uh, you know, as, [00:13:00] as everyone's thinking about Thanksgiving tomorrow and indulging, uh, you know, these NAD therapies like in a man have already shown protecting his diet and use their obesity.

[00:13:08] So, you know, maybe think about doing some NMN seminar or you know, if you have it, the five from, you don't want him cute.

[00:13:13] Carl Lanore: [00:13:13] So it is the five of me, no one MQ available yet to TaylorMade for the practitioners that are listening.

[00:13:19] Ryan Smith: [00:13:19] It is. It is. Um, and, uh, and I, you know, I, we can sort of go over dosing, but yeah, it's really bioavailable.

[00:13:26] Um, and we recommend taking it on a daily basis. Um, one of the things that I also want to mention is that the really popular nav strategies only raised in D levels for a short amount of time. We're talking, you know, on the scale of minutes. Um, but by inhibiting this enzyme, you get long lasting increases in nag.

[00:13:45] Uh, instead of minutes. You know, you've, we're talking hours. And so, um, this is another reason that this time supplementation is a little bit better than even the nav precursors.

[00:13:54] Carl Lanore: [00:13:54] Have you been able to determine, or can you even guess why. This enzyme [00:14:00] rises as we age. Have you looked at downstream contributors and go, Oh, well, here's why it's going up.

[00:14:05] As we age.

[00:14:07] Ryan Smith: [00:14:07] Yeah. And so, um, there are a lot of theories on that. Um, but I don't know that it's, it's, it's thoroughly elucidated. I think that, um, you know, the, one of the biggest things, um, that happens is just the increased need for methylation, um, in order to regulate the epigenetic genome.

[00:14:26] Um, and so, um, you know, that's one of the things we see as a decrease. So we only. With that being said, we talk a lot about the, um, we've talked a lot about the increasing the NAD and the results that it has on cellular metabolism, but we actually see with this product, another co-factor go up as well, which is what I mentioned earlier, that that acid didn't on the timing or Sam.

[00:14:46] Um, and that's an important cofactor for a variety of reasons as well. Um, some of which relate to, uh, uh, where did we call it? Poly mean flux, which is. Yeah. Which is

[00:14:58] Carl Lanore: [00:14:58] really a magical [00:15:00] pathway that is probably more misunderstood today, and I think that some of these breakthroughs are going to force scientists to start looking more at the polyethylene flux pathway.

[00:15:12] Ryan Smith: [00:15:12] Absolutely. And you know, I wouldn't claim to be an expert on it by any means. I don't

[00:15:15] Carl Lanore: [00:15:15] think anybody is. Right. Maybe bill, maybe bill can be, that's

[00:15:19] Ryan Smith: [00:15:19] it. Follow this up. But uh, yeah, no, it is also another pathway which is involved in, in Annapolis. Anabolism and so it can help with, uh, you know, increasing lean muscle mass.

[00:15:32] It can help with all the same pathways. Um, that, uh, you know, we increase when we increase, you know, there's the anabolic state. Um, and so, uh, by, by doing some of that, we're also encouraging some muscle changes, um, which we also see, which in the second really, really popular study they did in people from mice as well.

[00:15:52] Carl Lanore: [00:15:52] And what was that that we love in this audience? We love anabolics. We love M tour. We're not [00:16:00] afraid of . Nope. Nope. A few people in my audience are taking daily dose of Metformin. Some of them are absolutely including myself using a periodic doses of, of rapid myosin for selective  receptor suppression.

[00:16:14] But the reality is we're all about building muscle. So talk about a little to get a little deeper and the, does this affect M Tor? How does it build muscle? Talk about that. Yeah.

[00:16:25] Ryan Smith: [00:16:25] So, um, it definitely would probably have an effect on him tour, uh, but we don't know for sure because it hasn't been studied.

[00:16:32] What we do know though, is, uh, there are various unlikely pathways which exist there. Before I go into those, I think that it's important to talk about its effect on the muscle just generally. And, and, um, one of the effects on one of the effects it has on muscle is to encourage repair and recovery by activating.

[00:16:49] Satellite STEM cells, muscle STEM cells in these tissues. As we age, um, we increase our muscles, our senescent muscle STEM cell pole, [00:17:00] and these potentially, like most of us themselves are, are just sitting around metal

[00:17:05] Carl Lanore: [00:17:05] making, making everything around them sick. It would be fine if they were zombies and they just kept to themselves right.

[00:17:11] Ryan Smith: [00:17:11] Exactly. Exactly. And so they're there and they're just causing damage. They're not doing their job, but they're just there. And so, um, what this is able to do is reverse that a little bit. So it's not, it's analytic. It's not going to kill those cells, but what it does is sort of activates them back to  state.

[00:17:28] And so what we've seen, and this is actually, um, you know, I didn't even know this when we first started doing it. Um, uh, you know, I, I had my, a tremendous response personally. To this. Um, and then I was talking with a couple of other physicians and it was saying, Hey, why in the world did I get this amazing response?

[00:17:46] Um, and then dr actually, Betsy, you're a few you've had on, um, came to me and said, Hey, look at this study. Um, and showed it to me. And what it showed is that it activates these muscle STEM cells, um, to increase repair and [00:18:00] recovery of muscle tissue. And so in mice, they induced damage in, um, particularly old mice because this is upregulated as you age.

[00:18:07] Uh, they saw a two X increase in muscle cross sectional area after injury, um, and they saw a 70% increase in contractile force. And so, uh,

[00:18:17] Carl Lanore: [00:18:17] we know that it has an ergogenic effect.

[00:18:20] Ryan Smith: [00:18:20] Absolutely. 70%, too. And, and this is exactly, uh,

[00:18:24] Carl Lanore: [00:18:24] going back to  and you experienced this, this increase in strength over what period of time of usage.

[00:18:31] Ryan Smith: [00:18:31] Yeah, so two weeks, um, which is pretty incredible. Um, and, and beyond that, the studies that were done in mice on muscle with it at two different durations one week, um, and then a long longer term duration. Um, and the longer term duration is what had the 70% increase in contractile force. But, um, my experience in two weeks was, was pretty insane.

[00:18:52] Um. You know, we, we started an intramural basketball league for the compounding and, and, uh, and I know this is gonna [00:19:00] sound crazy, but you know, in two weeks I was able to gain seven inches on my vertical. It was night and day in the gym. It was unreal. I couldn't believe it. And I wouldn't, the only two factors that changed in those two weeks were.

[00:19:12] That I'd got new shoes and started the five of me on one MQ. That was the only change, but I was able to, you know, I was barely able to touch, touch Ram with your hands, and I was doing, you know, one 80 dunks in two weeks and there's nothing else to change. And that's such a big difference. Have you stopped using,

[00:19:27] Carl Lanore: [00:19:27] have you stopped using it now?

[00:19:29] Yeah, I have. I saw a, just a, I think a reversal of fortune. Um,

[00:19:36] Ryan Smith: [00:19:36] unfortunately, yes. Um, but not, not a complete reversal. Um, but, uh, but, but definitely not as, not as high performance. And so, um, and so if it has been, I now I've been off of it for over two and a half months, and so. You know, it's, it's been a little bit of a duration.

[00:19:51] So, um, but again, so it has that effect on muscle. We know what's happening with repair and recovery and that, again, increasing that contractile force, which [00:20:00] is something that, again, I experienced but didn't know him prior as a, as a possible reason.

[00:20:05] Carl Lanore: [00:20:05] So I use post-workout oxytocin because of the one study that I talked about several years ago on my show where they gave old rats.

[00:20:14] Uh, oxytocin and their muscles recovered as fast or faster than young rats. So I take, um, I take about 50 IUs of oxytocin post-workout for that purpose. And boy, do I get a head rush from it, by the way? Uh, and, and, uh, I, I would, it sounds like I could stack oxytocin with this.

[00:20:36] Ryan Smith: [00:20:36] Yeah. Yeah. You know, I mean, absolutely.

[00:20:39] I think that, um, you know, there's even some good data on oxytocin, uh, you know, prior to meals, uh, to reduce,

[00:20:46] Carl Lanore: [00:20:46] yeah. Improve satiety. Yeah. And, and before lovemaking, it improves the orgasm. So it's a great hormone. It really is compared

[00:20:56] Ryan Smith: [00:20:56] to that. But by that, I mean, it doesn't sound

[00:21:00] [00:20:59] Carl Lanore: [00:20:59] so good.

[00:21:00] Now with the five amino is, I mean, the oxytocin never made anybody jump seven inches higher than they could before. So let's be on, I think I could see them stacking to improve muscle recovery and us older rodents. Uh, but, but I, I don't think oxytocin's ever going to do what this, especially when it comes to, again, oxytocin seems to improve satiety, reduces hunger.

[00:21:22] So it has an extrinsic effect on, on body composition. But this is an intrinsic effect, its direct effect on body composition.

[00:21:31] Ryan Smith: [00:21:31] Absolutely. Yeah. It definitely, in terms of that metabolism, and we know that because the diets of these mice didn't change. Right. Um, and so irrespective of these high fat diets, we saw increased metabolic rate and decreased fat mass.

[00:21:43] And so, uh, going and going more to the indoor side of things. Um, the interest stuff is a little bit speculative. We do know, uh, there've been several good studies about the ability for M Tor to actually regulate the poly mean flux cycle. And so we know that. It can do this by [00:22:00] essentially, um, phosphorylating a particular enzyme, uh, to, to convert the Sam, um, to its co-factor in the, in the Pauline flux pathway.

[00:22:11] And it sort of locks it in there so that the poly mean plucks pathway can use it as a catabolic process. And so again, we're just, it's nothing we haven't heard before. We're inventory is acting as that master switch to encourage anabolic processes. Right. Um, and so w the, the con, the other side of that though, is that oftentimes, uh, you know, when people talk about longevity, they talk about fasting.

[00:22:32] They talk about, you know, changes in body temperature, cold and, and hot. And, and it actually in this heat shock proteins, um, exercise. The other big thing that has been talked about is restriction. I'm refining the amino acid methionine as a way to to handle this, and so metallothionein converts to.

[00:22:51] The Sam product, the ECET dental Messiah name, and that, um, product is involved in a pathway with, um, essentially two [00:23:00] different, uh, regulators of M Tor, which are Gator. And then a newly identified co-factor called Sam tour. And what happens is, in the absence of, um, in the absence of . We can actually, uh, block, you know, him tour by this whole, these three protein interactions.

[00:23:19] And so, um, the because of that, we would anticipate that increasing this Sammy or Sam am on this particular product would actually, uh, increase him towards activity, um, instead of decrease it. Um, but again,

[00:23:35] Carl Lanore: [00:23:35] uh, so a couple things come to mind. I have so many thoughts running through my head right now.

[00:23:41] Um, so, uh, from a, from a muscle building standpoint, obviously, uh, that's going to turn up the metabolic machinery also, right? I mean, that's gonna have an effect on, on fat acquisition. I know a lot of people in my audience are probably saying to themselves right now, but we know that [00:24:00] a high fat diet to rodents is worse than a high fat diet to humans.

[00:24:04] So I have to ask you about. Uh, another pathway, and that's a, you know, uh, glucose signaling. Do you think that it'll have an effect on humans who are, uh, prediabetic or going down that path and not because of their fat intake, but because of their raging blood sugar and take because of the high carb loads.

[00:24:25] Ryan Smith: [00:24:25] Yeah. And so, uh, we would definitely believe that it's going to have a, a response and most likely a positive response. We know that, um, it's going to decrease the, the lysis, which is means that you might have some circulating free fatty acids that you wouldn't have, um, otherwise, but, but generally we would say it has a positive effect because it's increasing this metabolic currency.

[00:24:45] You know, it's a increasing museum, AP levels. And, and, and beyond that, it's also having a muscle building effect, which is the metabolic currency of the body. Right? So we think we'd have an effect, but it's pretty speculative at this point and we don't have a lot of data as it relates to our patients.

[00:25:00] [00:25:00] Um, I wear a continuous glucose monitor, um, a lot of the time, and I can say that I haven't seen really any changes in my life because as a result of the divide for me now

[00:25:09] Carl Lanore: [00:25:09] I want to take a quick commercial break. When we come back, I'd like to talk about dosing duration, potential side effects.

[00:25:14] And all that sort of stuff. How's that sound? Sounds great. Okay. And if you're interested in this, have your doctor contact tailor made pharmacy in Nicholasville, Kentucky right here in my state. That's right, baby. We're changing things from Kentucky. Stay tuned. We'll be right back. Welcome back to the pep talk with Ryan Smith from TaylorMade.

[00:25:36] And while this isn't a peptide, it's a very, very interesting molecule that may have some profound benefits to many people in the audience. And those people will be the same people that embrace peptides because we're all about things that actually do something positive and don't just mask a symptom.

[00:25:50] So talk about dosing duration, any side effects to be concerned about. Yeah.

[00:25:56] Ryan Smith: [00:25:56] So for this, we're going off of a very limited clinical data. [00:26:00] Um, and so what we did initially is took a conservative approach to the, the animal dosing and dose conversion using surface area. Um, conversions that are, are pretty, you know, well established.

[00:26:11] Yeah, yeah, exactly. And so what we generally recommend is anywhere from a hundred to 150 milligrams on a daily basis. Um,

[00:26:20] Carl Lanore: [00:26:20] okay, wait, wait, so, so I'm gonna, I'm gonna jump in and cause I, I want detail. So split across two doses, taken in the morning on an empty stomach. How about pre-workouts since it seems to liberate free fatty acids?

[00:26:32] Ryan Smith: [00:26:32] Absolutely. And so that is a, that is typically where we recommend is, you know, fasted in the morning on an empty stomach. Um, and we do, this actually is as 50 milligram capsules. And so this allows for some flexibility in dosing. If you wanted to do 50 milligrams vid or you wanted to do all 150th three capsules in the morning.

[00:26:52] Um, and so, so we do it as three different capsules. One of the other reasons we do the three capsules is, um, we haven't seen very many side effects, but [00:27:00] one that we, I would say we've seen just a little bit is, um, some provocation of anxiety. Um, and just having an increased heart rate. Right.

[00:27:08] You know, sort of after administration. Um, and you know, we, we're not really sure why that might be. We might be,

[00:27:15] Carl Lanore: [00:27:15] cause I was gonna I was gonna say, have you checked blood sugar after dosing? Go ahead. Why do you think that is? So

[00:27:21] Ryan Smith: [00:27:21] I do a a, so I do a continuous glucose monitor. So I, you know, I don't see a big decrease.

[00:27:26] However, with that being said, you know, uh, um, you know, I probably don't want one. He's taken that data, so it might be interesting to, uh, to see that further, but it might be also the NAD, you know, increasing those NAD levels. We know that NAD therapy is. You know, some of that typical side effect.

[00:27:42] Um, and it's pretty uncommon I would say as well. You know, only a few people, uh, have ever experienced it with this product and going at, you know, pretty high doses as well. Um, and so that, that dose is, is typically what we would recommend. And you can do that pretty consistently. Um, at the moment, uh, you [00:28:00] know, we do recommend taking breaks, like I mentioned that I did.

[00:28:03] And the only reason we say that is because we're not sure how. Chronic administration of this enzyme blocker might have an effect on the enzyme levels. Uh, for instance, you know, if we block it, will the body increase production of this

[00:28:16] Carl Lanore: [00:28:16] enzyme? It's funny, it's funny you say this, it's so people, a lot of people found out about a decade ago that this phenomenon occurs with the suicide, aromatase inhibitors like anastrozole.

[00:28:26] So guys would take Anna's resolve and the body tries to correct the imbalance by producing. More aromatase enzyme. And, and so when they would stop taking the honest result, they would have this boom around effect boomerang effect, where their, their estrogen levels, the estradiol levels would go through the roof.

[00:28:44] And people were like, this doesn't make sense. And it's because the body is always fighting to find homeostasis. So when you, and the other problem is you don't know what effect just has on any downstream enzymes, that this enzyme is a precursor to.

[00:29:00] [00:28:59] Ryan Smith: [00:28:59] Correct. Yeah. So it's a little bit of speculation, and like I said, I know, we know that, uh, in particular by increasing the NAD, plus we're activating, you know, uh, where it's a cofactor for, is it CD 38 sales to cofactor for, uh, the parks, you know, it's a cofactor for, um, the . And so we know it has a lot of you by increasing this co-packer, we might be . Encouraging the production of a lot of downstream things.

[00:29:22] Um, and so we do, we do recommend taking a break. And so usually we, we were pretty cautious, say a month on a month off, um, at the moment, um, maybe even more than that off. Uh, obviously I've done a little bit over, you know, two and a half months, but, um, but, but we do recommend a, you know, just just to short durations.

[00:29:38] Um, and you know, this also would be for people who are trying to lose weight, but also for those people who are trying to repair and recover from injury, particularly if they're advanced in age.

[00:29:50] Carl Lanore: [00:29:50] So that's a good point. So if you do have a muscle injury you like, I've torn more muscle bellies and over my life and some of them were very bad [00:30:00] needed, you know, attachments needed to be reattached.

[00:30:02] But do you think this, this could be a tag team with BPC one 57, a, uh, uh, a growth hormone secreted Gog and this to speed up healing post surgery or post injury.

[00:30:15] Ryan Smith: [00:30:15] Absolutely, yeah. The, the a is now even been, I would say, implemented in a couple of cocktails with the VPC diamond, some beta for M and a.

[00:30:24] And so that, that, that combination is already happened clinically. And, uh, and hopefully we'll have some good reports back here with the next few months.

[00:30:33] Carl Lanore: [00:30:33] Very, very interesting. So, um, I guess it's not wise to take it at night if it potentially could have a stimulatory effect. Right.

[00:30:41] Ryan Smith: [00:30:41] Correct.

[00:30:42] And then beyond that, I think we see maybe some increased energy as well.

[00:30:46] Carl Lanore: [00:30:46] And that was my next question. So do you see an increase in energy? It was exactly

[00:30:49] Ryan Smith: [00:30:49] when variable. Um, but, but, but definitely energy is, it relates to, I would say even endurance exercise. Um, and, uh, but even just a, you know, a little bit of [00:31:00] a lifting benefit.

[00:31:01] Um, and, and also we know that some of the downstream effects of, you know, supplementing with . Sammy could be, you know, reducing depression, for instance. And so that might be possible, uh, you know, mechanization for its mood, lifting benefits as well, besides the, um, but, uh, yeah, speculating that,

[00:31:17] Carl Lanore: [00:31:17] uh, any, any effect on redox or oxidative stress at all in this

[00:31:22] Ryan Smith: [00:31:22] equation?

[00:31:23] Um, so not that we've seen, or I should say, not that we think we know that. Um, so again, if we're acting as a, you know, the, uh. Well, I was talking about this Pauline Fox pathway. There's lots of talk about there. Um, but one of the ways, uh, you know, the, a lot of the ways that pathway can work is by, uh, you clear a lot of these poly means.

[00:31:45] What can happen is you can deplete ATP, which acts as a sensor to activate kindness and an activity, PGC one alpha, which activates oxidative hospitalization. So, um, I would probably say that, uh, we probably wouldn't see an increase in oxidative hospitalization [00:32:00] as a result of the polynomial flocks, but we could as just the NAD cofactors, um, increasing some of that, that cellular metabolism.

[00:32:07] Carl Lanore: [00:32:07] No. I asked you in a, in a text message one day, does it, does it stand to reason to stack this with NAD plus and you said really not, huh? Well. Yeah.

[00:32:17] Ryan Smith: [00:32:17] So I think that what we do and what we see is that, um, you know, even if you, I don't, some people would be postulated that the idea of using a, a cofactor, a precursor, like the NMN with this or the ENR.

[00:32:29] Um, and I think that what we see is just . Such increase the levels of the NAD already, that it's probably not necessary. Um, and what we actually see with the NMN is that actually cellular levels of  don't increase. And the reason being is they think it converts so rapidly, the NAD. Um, and so, and so with that being said, you know, I don't know that any of the precursors that were in NAD would really even be necessary in combination with this.

[00:32:54] Carl Lanore: [00:32:54] Yeah. Especially if you're upregulating intracellular. Uh, an a D and that, and that's where you really wanted [00:33:00] anyway. Um, this, this is not necessarily in your wheelhouse, but I know that you are an athlete type and, uh, and, and so Mark de Corso says, uh, is fat obesogenic and the presence of any carbohydrates essentially is the kedo diet.

[00:33:14] Really the only healthy high fat diet. And you, you, you convoluting so high fat. And obesogenic. I'm sorry, healthy and obesogenic really don't have anything to do with each other because you can starve yourself or develop kikexia and lose weight. And that's not healthy. But, um, I would say that no fat is not obesogenic in the presence of carbohydrate because bodybuilders eat fat and carbohydrates and get ripped.

[00:33:37] And I know they use drugs, but still, I mean, there's a lot of natural bodybuilders out there who combined fats, carbohydrates, and proteins together. What are your thoughts on that?

[00:33:47] Ryan Smith: [00:33:47] Yeah. No, I would probably say the same thing. Although again, I'm not in definitely not an expert. Um, you know, but, uh, I can tell you from, from what we've seen with a couple of other products in particular, things like the, you know, MOTC the [00:34:00] Motzy, uh, what we know is that dirty Quito still works.

[00:34:04] Um, and, and it can work. Do you have a variety of mechanisms is as long as you're getting the right to tell you the signals which are increasing amp kinase, increasing those glute four receptors, increasing the oxygen posturization so we know dirt can still be a great way to lose weight.

[00:34:17] Carl Lanore: [00:34:17] So dirty keto, meaning that you're really eating carbohydrates along with your high fat diet.

[00:34:22] Correct.

[00:34:23] Ryan Smith: [00:34:23] Then you're not, not a high amount, but, but some of it there too.

[00:34:26] Carl Lanore: [00:34:26] Yeah. I've never heard it called that, but I guess dirty Quito is considered low carb. You

[00:34:31] Ryan Smith: [00:34:31] know? That's exactly

[00:34:32] Carl Lanore: [00:34:32] what I think is a much more sensible diet. Personally, I've been low carb for ever since I could remember, and I choose my carbohydrates wisely.

[00:34:40] I try to make them. You know, green vegetables, green beans, and spinach and broccoli. I love broccoli, unlike president Bush the first. But anyway, um, so anything else we should know? And then I have some random questions I want to ask you. Anything else we should know about this? This ma Oh.

[00:34:57] What is, what is a a patient [00:35:00] looking at as far as a monthly expenditure? If they're going to do a month on a month off, let's say for six months, so they're going to buy, what's a monthly cost target for this particular unique molecule, which isn't available anywhere else.

[00:35:13] Ryan Smith: [00:35:13] Yeah. Correct. And it's also, I'm not available as any type of supplement.

[00:35:17] This is really the only pathway, but um, you know, genuinely depends on the dose. Usually if you're doing around a hundred milligrams a, it's going to be around $240.

[00:35:26] Carl Lanore: [00:35:26] That's very reasonable. Absolutely. But doing 150 milligrams a day, we're talking about under $300. Right.

[00:35:34] Ryan Smith: [00:35:34] Absolutely. And it is, especially if you look at the other things in the class, like in the men in a, and it's actually pretty prohibitively expensive at high doses.

[00:35:42] And so, um, so, and with this being a alternative to, in a man, you know, you're looking at a, uh, a very reasonable, uh, you know, cost benefit ratio.

[00:35:52] Carl Lanore: [00:35:52] Um, so these questions are result of. Questions I've received from other people. And they're also [00:36:00] things that a lot of people probably, you know, when you receive a question from somebody, chances are there's a dozen other people who feel the same way.

[00:36:05] So, best dilute for current, uh, uh, stock of peptides, uh, sodium chloride, uh, bacteria, static bacteria, static or just, uh, uh, water for injection.

[00:36:21] Ryan Smith: [00:36:21] Yeah. So this is a question I get. We get a lot, and, and the, I would say that the biggest misnomer is that it really matters a ton. It honestly does not matter a ton.

[00:36:32] Um, however, there are a few exceptions where it does matter. Um, in particular, the testimonial Lynn is one of those that I would recommend sterile water exclusively. Um, and I would generally say that sterile water, you can't go wrong with it. Um, just regular Serra water, the, um, you can't go wrong with the bacteria static in some scenarios.

[00:36:51] Um, but the issue with the Sarah Waters, obviously sterility, um, keeping it sero after multiple punctures, uh, but usually you're not going to worry about [00:37:00] decreasing the potency of any peptide after reconstitution, which just that product, however, you also do increase your risk of injection site reaction just because it can be a little bit irritating as it relates to Austin.

[00:37:10] Larry.

[00:37:11] So

[00:37:12] Carl Lanore: [00:37:12] I, I've always used sodium chloride for injection because my logic was it's actually saline. And that's what that is. What the basic fluid in a body is. It's, it's, it's saline. I learned that when I was in optometry school for eyedrops and you know, buffered saline, blah, blah, blah. So I've always used bacteriostatic sodium chloride, and quite frankly, I have like two huge trays of it to go through.

[00:37:38] I don't want to throw it away, so I'm safe using it for everything except tests. Morella.

[00:37:43] Ryan Smith: [00:37:43] Yeah. And even with the testimonial, and I don't think that you're going to even experience a clinically relevant decrease in potency. Um, but, but it is important to notice that that has to establish.

[00:37:53] Carl Lanore: [00:37:53] Okay.

[00:37:53] Which leads me to the next question. One of the greatest peptides in the world to help people anecdotally [00:38:00] figure out shelf shelf life as well. I know, tend to, so

[00:38:03] Ryan Smith: [00:38:03] I have

[00:38:04] Carl Lanore: [00:38:04] a, I have a 10 milligram vial of Velano ten two that's like, Oh year old and it's reconstituted with sodium chloride.

[00:38:12] Bacteriostatic water and it still works. So what? What is shelf life variable based on the bonds and how delicate this peptide is from one peptide to the other. Are we making much to do about nothing that these things stay pretty much intact in, in, in the fridge a lot longer than we think they do.

[00:38:32] Ryan Smith: [00:38:32] Yes. And so they're not nearly as fragile as everyone builds them out to be. However, there are definitely some exceptions to the rule. Um, you know, one of the biggest exceptions to that rule is the emote CSC. It's, you know, even just reconstituting it, it causes 90% degradation. Four hours. Um, and so you're talking, if you leave it in there for two hours, you're causing a 50% decrease in its potency.

[00:38:56] And so, uh, there are exceptions to the rule as it relates to UV [00:39:00] light, um, as it relates to, to, you know, just about everything, which is another reason we encourage people to go to pharmaceutical sources because that's one thing we have to do is in order to provide it, we have to make sure that it's going to maintain it.

[00:39:12] If potency, uh, for a certain amount of time, we're going to have to find out a way to do, or we're going to have to make sure it reduces reactions. That's correct. pH, all of those factors. And so if you are reconstituting it, I would say don't worry really too much, but for try and limit it to usually, I would say two weeks or four weeks

[00:39:28] Carl Lanore: [00:39:28] of supply.

[00:39:29] We talk about all peptides other than MTOs. Okay.

[00:39:34] Okay.

[00:39:34] Ryan Smith: [00:39:34] I would say most of the ones that are frequently used, uh, by the general population, they're really, really talking to the ones that are relatively stable. The Melana TNT was exceptionally stable as it's cyclic, um, and, uh, and so it has a, some additional resistance to degradation.

[00:39:50] Carl Lanore: [00:39:50] Okay. Uh, here's one that I think that you should check out and I'll have you back on the show, even if it's just for 10 minutes to go. No, call you a wrong . I would love to [00:40:00] see what, uh, what cellular telephone radiation does. The peptides.

[00:40:03] Ryan Smith: [00:40:03] Yeah, I, uh, yeah, no, I wouldn't, um, that's an easy experiment for us to do.

[00:40:08] We can run it in the mass spec, you see behind me, and we can, uh, we could do it. I, I've never thought about that, but it would be worth if you're very right, we

[00:40:16] Carl Lanore: [00:40:16] know, we know that cellular telephones are. Affecting us on a cellular level. We know that it affects, uh, neurons in the brain. If you have a cell phone call, uh, you take you up to an hour longer to get into deep sleep.

[00:40:29] If you have a cell phone call within a half hour of going to bed to take you up to an hour longer to get into your deep sleep phases, we know that it has an excitatory effect. We know that it has a mild oxidative effect and we're learning now. I mean, I did a show earlier this year that showed that the cilia.

[00:40:45] On cells act like antennas and they attenuate different frequencies anywhere from two a two millimeters to two microns. And the higher the frequency, the smaller the antenna. [00:41:00] And we already know that there is now developing a link between adult onset of mitral valve, dysfunctional prolapse and people who keep their cell phones in their pockets.

[00:41:13] Oh, so, so, you know, we know the cell phones are doing stuff to us. And I've always wondered, I wonder when, cause I, you know, I'll take my cell phone and throw it in my backpack. I'll take my peptides and syringes and throw it in my backpack. I'll go to the gym. And I think to myself, I wonder if like they're dancing in there and you know, like a radiation is making them dancing.

[00:41:33] It's ruining them. I, it's a good question. I think somebody needs to get to the bottom of it.

[00:41:37] Ryan Smith: [00:41:37] Yeah, very good question. And one that one that I've not seen any data on. It also brings up the question of how it effects peptides in the body, right? And so, uh, um, you know, I think that there's the experiments to do and one that will give you back a month.

[00:41:50] Carl Lanore: [00:41:50] Well, and this next question in the last one I'm going to ask you, cause I know you're busy and you've taken time out of your day to be here today. Uh, this next one I asked Anthony Roberts this a decade ago, right? So [00:42:00] I've been putting the same peptides in one syringe forever. And then somewhere along the line, uh, I had people say, Oh, you know, John crystal came on my show, may he rest in peace?

[00:42:12] Uh, probably four or five years ago. He says, no, don't do that. We don't know how they buffer together. And then I started hearing about bonds and attractions and I thought, well, maybe this makes sense, but now I'm back to loading everything into one syringe. And cause I figured I'm going to use it in under an hour.

[00:42:30] Uh, like how much could actually happen. But with that being said, the logic, I use my critical thinking skills, I said to Anthony Roberts, these peptides seem to travel around in our blood and stay intact, and that they don't affect each other. Why would I think that if I've got it in an a and an a in a, a water based solution, that somehow all of a sudden all bets are off and these things are just going to conglomerate.

[00:42:54] Ryan Smith: [00:42:54] Definitely. And so the, the, you know, the, the real crux of the issue goes through what is, you know, [00:43:00] what is actually happening and what is actually clinically relevant. Um, you know, if you're combining these into multiple syringes, you can anticipate that they're going to have some reaction together.

[00:43:08] Um, you know, it, depending on the peptide link, depending on the peptide, you know, secondary structure or tertiary structure, um, some of these even caused dimerization or protein aggregation.

[00:43:19] Carl Lanore: [00:43:19] I've seen that. I've seen that every now and again. No rhyme or reason. Same peptides I used yesterday, but today I'll see this little, this web of cloud form in the middle.

[00:43:30] I know. I go, Oh, all those peptides probably just stuck together right there.

[00:43:34] Ryan Smith: [00:43:34] Yeah, it's definitely possible they can dimerize and form larger chains and, and do the whole thing. But usually if you're mixing them in a relatively dilute solution that has been pH correctly, and, um, I would say it's not usually an issue.

[00:43:50] But with that being said, uh, as a pharmacy, we can legally only say to not combine them.

[00:43:56] Carl Lanore: [00:43:56] Yeah. Okay. All right. That makes perfect sense. Um, I [00:44:00] think we've covered a lot of ground and this is really interesting. So people can go, have their doctors contact, tailor made, and they can start using five amino, uh, uh, one MQ.

[00:44:10] And it sounds like you'll know whether it's working for you pretty quickly. Yeah,

[00:44:16] Ryan Smith: [00:44:16] definitely. You know, we've seen it. The weight loss effects, uh, you know, taking a little bit longer. Uh, I would say, yeah, 40 weeks, but, but in terms of performance benefits, those are noticeable quickly.

[00:44:27] Carl Lanore: [00:44:27] Yeah. I could see this being a really hot peptide.

[00:44:30] I mean, peptide, uh, a small molecule in the, in the powerlifting community. Imagine being a power lifter and being able to use this and even even increasing strength 5%. We're talking about, we're talking about breaking your own PRS very quickly.

[00:44:46] Ryan Smith: [00:44:46] Definitely. And, and beyond that, you know, increasing repair recovery, right.

[00:44:50] And so, uh, and decreasing the muscles STEM cell senescence and increasing that muscle STEM cell full, uh, which might make you more receptive to, you know, things like the peculated MTF [00:45:00] or, uh, you know, a lot of those other muscles, specific peptides and stimulators in proteins. Oh yeah, absolutely.

[00:45:07] I could see it being big in that world as well as the weight loss world, as well as the repairing recovered world is, uh, you know, they're there, uh, even then go on jeopardy world as well. So I think there are a lot of applications for this product.

[00:45:17] Carl Lanore: [00:45:17] I'd, the longevity standpoint, you would postulate that this would affect longevity through, uh, through effecting senescent cells.

[00:45:25] Right. Which is like the, that's the GoTo lowest common denominator now. Right. Correct.

[00:45:30] Ryan Smith: [00:45:30] Having a cofactor for those are two ends. So those situations are able to do their job and use that epigenetic drift. Um, and so between those two or, you know, I think that, uh, yeah, we definitely have an a, hopefully an annotation, but if it as well.

[00:45:45] Carl Lanore: [00:45:45] Excellent. Excellent. Look, I want to thank you so much for being on the show today. Always a

[00:45:49] Ryan Smith: [00:45:49] budget. Thanks for making it happen.

[00:45:50] Carl Lanore: [00:45:50] And after you get your cell phones, uh, experiment done, please come back on and say, no, Carl, you will completely wrong.

[00:45:58] Ryan Smith: [00:45:58] Perfect. Regenerate. You can definitely [00:46:00] give it a go probably in a couple of weeks.

[00:46:01] Okay.

[00:46:01] Carl Lanore: [00:46:01] Thanks a lot. Thanks a lot. All right, we're going to just run one last commercial break cause I have to pay bills. So state, this

[00:46:10] Ryan Smith: [00:46:10] is the superhuman channel

[00:46:12] Carl Lanore: [00:46:12] doing reps

[00:46:13] Ryan Smith: [00:46:13] with the weight of the world.

[00:46:18] Carl Lanore: [00:46:18] So a quick follow up, I almost forgot about this.

[00:46:22] Ryan Smith: [00:46:22] Those

[00:46:23] Carl Lanore: [00:46:23] of you who have already tuned out, you're missing out. Oh, you're going to be eating lots of food in the next couple of days. And the truth of matter is. This month, right? As we go into December, we have Thanksgiving, we have Christmas, we have all these holidays that you'll be celebrating with your family.

[00:46:38] Leverage, leverage, leverage this opportunity to build more muscle. How? Okay. Easy. So when you eat after you train, we know there's an anabolic response. So before you eat, get down and do. A [00:47:00] couple sets of pushups, 20 at a time, maybe do a hundred pushups, right? Get down and do some body weight squats.

[00:47:06] Then sit down and eat. If you've got a home gym, go down and bust out a 15 minute routine and then eat and do that again and again because you know you're going to eat five or six times on Thanksgiving, you're going to stuff yourself. Why not turn on the anabolic signaling. As long as you're going to eat.

[00:47:24] You know Brooks Kubik and I talked about this probably five years ago, and we got contacts from people who said, I followed your advice and I put on a pound of what can only be muscle because they saw it in the mirror. And so take a shot, try setting up your eating to priest, pre-seed your eating by doing some.

[00:47:50] Hard work. I don't care if it's picking up a couple of dumbbells and going for a walk up the street and back and then eating. Anything like that is going to change the way your [00:48:00] body handles those calories. I can guarantee it and then let me know if it works. I will be doing it. Actually, we have two Thanksgivings.

[00:48:07] We have one tomorrow at the house. And then we have one tonight where we take a dinner to Elisa's dad because he doesn't get around anymore. And so I know that I'm going to probably bust out some pushups and some body weight squats before I eat this evening, and I'm going to do it every time I eat tomorrow.

[00:48:25] I'm going to leverage this opportunity to actually add muscle. Don't forget. You'll, you may be saying to me all call, this is the, this can't work. Well, think about the Bulgarian for a second. They would train five or six times a day. They would eat. Now, granted, they will go into the gym and training for 45 minutes.

[00:48:44] Don't get me wrong, I'm not saying you're gonna, you're gonna max out your dead lift because of this, but you absolutely can redirect where those calories go by training for 15 minutes. Yeah. I mean, do just bust [00:49:00] out a hundred pushups at 10 at a time if that's what it takes, and then go eat. That alone will change the outcome of this holiday season.

[00:49:09] So take my advice. Have a happy Thanksgiving. We got lots of great shows next week. I'm gone for the rest of the week. Uh, so hope all of you have a lot to be thankful for. I do. You know what? I'm thankful for every one of you right now listening to this podcast or watching you make me thankful. .